Aquestive Therapeutics adds Richard Daly to board
Aquestive Therapeutics announced the appointment of Rich Daly to its Board of Directors, effective October 14, 2026. Daly is described as a life sciences executive with more than 30 years of leadership across large pharmaceutical companies, emerging biotech, and public boards. The move is framed by the company as strengthening governance and strategic oversight as it advances its medicines and delivery technologies.
What changed
The company says Rich Daly is joining the Board of Directors. The appointment is effective October 14, 2026. Daly has roles in commercial and operating leadership across biopharma, including both large pharmaceutical firms and smaller biotech companies, as well as public company board experience. The news emphasizes governance and strategic input from a seasoned life sciences executive.
Who is affected
Quéstive Therapeutics shareholders and potential investors may be most interested, as board composition can influence strategic direction and governance. Employees and patients could be affected indirectly through potential prioritization of programs or shifts in strategic focus, though the company does not detail immediate product changes in this release.
Practical next steps
For readers tracking Aquestive, monitor announced filings and company updates around corporate governance and strategic commentary. If you are an investor, review the official press release and any subsequent regulatory disclosures for details on board responsibilities, compensation, or related governance changes. Consider how a new board member with a background in commercial and operating roles might influence long-term strategy for marketed medicines and delivery technologies.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- investingnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.